Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1500648800HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

FDA rejects Novartis AHF drug serelaxin; more efficacy evidence needed

16.05.2014 / Scripintelligence

Dr Tim Wright, global head of development at Novartis Pharmaceuticals, said the company planned to continue to expedite its clinical trial program to build the supporting body of evidence for serelaxin per the FDA's advice.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: